BACKGROUND: The neurosteroid allopregnanolone is a potent allosteric modulator of the gamma-aminobutyric acid type A receptor with anxiolytic properties. Exogenous administration of allopregnanolone reduces anxiety, and allopregnanolone blockade impairs social and affective functioning. However, the neural mechanism whereby allopregnanolone improves mood and reduces anxiety is unknown. In particular, brain imaging has not been used to link neurosteroid effects to emotion regulation neurocircuitry. METHODS: To investigate the brain basis of allopregnanolone's impact on emotion regulation, participants were administered 400 mg of pregnenolone (n=16) or placebo (n=15) and underwent 3T functional magnetic resonance imaging while performing the shifted-attention emotion appraisal task, which probes emotional processing and regulation. RESULTS: Compared with placebo, allopregnanolone was associated with reduced activity in the amygdala and insula across all conditions. During the appraisal condition, allopregnanolone increased activity in the dorsal medial prefrontal cortex and enhanced connectivity between the amygdala and dorsal medial prefrontal cortex, an effect that was associated with reduced self-reported anxiety. CONCLUSIONS: These results demonstrate that in response to emotional stimuli, allopregnanolone reduces activity in regions associated with generation of negative emotion. Furthermore, allopregnanolone may enhance activity in regions linked to regulatory processes. Aberrant activity in these regions has been linked to anxiety psychopathology. These results thus provide initial neuroimaging evidence that allopregnanolone may be a target for pharmacologic intervention in the treatment of anxiety disorders and suggest potential future directions for research into neurosteroid effects on emotion regulation neurocircuitry.
RCT Entities:
BACKGROUND: The neurosteroid allopregnanolone is a potent allosteric modulator of the gamma-aminobutyric acid type A receptor with anxiolytic properties. Exogenous administration of allopregnanolone reduces anxiety, and allopregnanolone blockade impairs social and affective functioning. However, the neural mechanism whereby allopregnanolone improves mood and reduces anxiety is unknown. In particular, brain imaging has not been used to link neurosteroid effects to emotion regulation neurocircuitry. METHODS: To investigate the brain basis of allopregnanolone's impact on emotion regulation, participants were administered 400 mg of pregnenolone (n=16) or placebo (n=15) and underwent 3T functional magnetic resonance imaging while performing the shifted-attention emotion appraisal task, which probes emotional processing and regulation. RESULTS: Compared with placebo, allopregnanolone was associated with reduced activity in the amygdala and insula across all conditions. During the appraisal condition, allopregnanolone increased activity in the dorsal medial prefrontal cortex and enhanced connectivity between the amygdala and dorsal medial prefrontal cortex, an effect that was associated with reduced self-reported anxiety. CONCLUSIONS: These results demonstrate that in response to emotional stimuli, allopregnanolone reduces activity in regions associated with generation of negative emotion. Furthermore, allopregnanolone may enhance activity in regions linked to regulatory processes. Aberrant activity in these regions has been linked to anxiety psychopathology. These results thus provide initial neuroimaging evidence that allopregnanolone may be a target for pharmacologic intervention in the treatment of anxiety disorders and suggest potential future directions for research into neurosteroid effects on emotion regulation neurocircuitry.
Authors: C E Marx; D W Bradford; R M Hamer; J C Naylor; T B Allen; J A Lieberman; J L Strauss; J D Kilts Journal: Neuroscience Date: 2011-07-01 Impact factor: 3.590
Authors: R Adolphs; D Tranel; S Hamann; A W Young; A J Calder; E A Phelps; A Anderson; G P Lee; A R Damasio Journal: Neuropsychologia Date: 1999-09 Impact factor: 3.139
Authors: Guido van Wingen; Frank van Broekhoven; Robbert Jan Verkes; Karl Magnus Petersson; Torbjörn Bäckström; Jan Buitelaar; Guillén Fernández Journal: J Neurosci Date: 2007-10-17 Impact factor: 6.167
Authors: E Romeo; A Ströhle; G Spalletta; F di Michele; B Hermann; F Holsboer; A Pasini; R Rupprecht Journal: Am J Psychiatry Date: 1998-07 Impact factor: 18.112
Authors: Pedro E Martinez; David R Rubinow; Lynnette K Nieman; Deloris E Koziol; A Leslie Morrow; Crystal E Schiller; Dahima Cintron; Karla D Thompson; Khursheed K Khine; Peter J Schmidt Journal: Neuropsychopharmacology Date: 2013-08-14 Impact factor: 7.853
Authors: Magali Comte; Aïda Cancel; Jennifer T Coull; Daniele Schön; Emmanuelle Reynaud; Sarah Boukezzi; Pierre-François Rousseau; Gabriel Robert; Stéphanie Khalfa; Eric Guedj; Olivier Blin; Daniel R Weinberger; Eric Fakra Journal: Hum Brain Mapp Date: 2015-02-09 Impact factor: 5.038
Authors: Israel Liberzon; Sean T Ma; Go Okada; S Shaun Ho; James E Swain; Gary W Evans Journal: Soc Cogn Affect Neurosci Date: 2015-05-04 Impact factor: 3.436
Authors: Xin Wang; Hong Xie; Andrew S Cotton; Kristopher R Brickman; Terrence J Lewis; John T Wall; Marijo B Tamburrino; William R Bauer; Kenny Law; Samuel A McLean; Israel Liberzon Journal: J Neurotrauma Date: 2016-06-27 Impact factor: 5.269
Authors: Ann M Rasmusson; Christine E Marx; Sonia Jain; Gail M Farfel; Julia Tsai; Xiaoying Sun; Thomas D Geracioti; Mark B Hamner; James Lohr; Richard Rosse; Lanier Summerall; Jennifer C Naylor; Cristine Cusin; Ariel J Lang; Rema Raman; Murray B Stein Journal: Psychopharmacology (Berl) Date: 2017-07-01 Impact factor: 4.530
Authors: Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong Journal: Psychopharmacology (Berl) Date: 2014-07-17 Impact factor: 4.530